Implementation of Sacubitril/Valsartan in Sweden: Clinical Characteristics, Titration Patterns, and Determinants

Abstract

Implementation of sac/val in Sweden was slow and varied five-fold across different regions; younger age, male, SwedeHF registration, and ischaemic heart disease were among the independent predictors of receiving sac/val. Overall, treatment persistence and tolerability was high.